Publications

Publication Search

Search for publications by

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Abstract

BACKGROUND: Patients with metastatic colorectal cancer whose disease has progressed on oxaliplatin- and irinotecan-containing regimens may benefit from EGFR-inhibiting monoclonal antibodies if they do not contain mutations in the KRAS gene (are

Type Journal
ISBN 1471-2407 (Electronic) 1471-2407 (Linking)
Authors Segelov, E.; Waring, P.; Desai, J.; Wilson, K.; Gebski, V.; Thavaneswaran, S.; Elez, E.; Underhill, C.; Pavlakis, N.; Chantrill, L.; Nott, L.; Jefford, M.; Khasraw, M.; Day, F.; Wasan, H.; Ciardiello, F.; Karapetis, C.; Joubert, W.; van Hazel, G.; Haydon, A.; Price, T.; Tejpar, S.; Tebbutt, N.; Shapiro, J.;
Publisher Name BMC CANCER
Published Date 2016-05-01 00:00:00
Published Volume 16
Published Pages 339
Status Published In-print